Skip to content

Depression research published in 2016

Page 3 of 6: studies 41 to 60 of 107, newest first. Back to the depression overview

Studies

Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.

Psychopharmacology Bulletin August 15, 2016 Edward C Lauterbach

Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.1,2 This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a...

Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial)

Pilot and Feasibility Studies August 3, 2016 Martha Finnegan, Karen M. Ryan, Enda Shanahan et al. 4 citations

BACKGROUND: Major depressive disorder is a common debilitating illness that is the second leading contributor to the global burden of disease. Unfortunately, about 30 % of patients do not respond to adequate trials of antidepressants and/or psychotherapies. About 45-60 % of such treatment-resistant patients will remit with electroconvulsive therapy (ECT). However, relapse rates are high...

New use for an old drug: oral ketamine for treatment-resistant depression

BMJ Case Reports August 3, 2016 Kevin Swiatek, Kim M. Jordan, Julie H Coffman 17 citations

Treatment-resistant depression (TRD) is a disabling disorder that can interfere with a patient's capacity to understand and participate in medical care and thus negatively impact individual morbidity and mortality. Hospitalised patients with TRD may require rapid alleviation of severe symptomatology, particularly when suicidal or if unable to participate in care decisions. Ketamine is well...

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

Psychopharmacology August 3, 2016 Bangkun Yang, Ji-Chun Zhang, Mei Han et al. 93 citations

RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression. OBJECTIVE: We compared the rapid and sustained antidepressant effects of R-ketamine and rapastinel in the social defeat stress model. RESULTS: In the tail suspension and forced swimming tests, R-ketamine (10...

DOI: 10.1007/s00213-016-4399-2 (opens in new tab) Full text (opens in new tab) Ketamine Social defeat Behavioural despair test Nmda receptor +11

The Effects of Mindfulness-Based Cognitive Therapy and Cognitive Behavioral Analysis System of Psychotherapy added to Treatment as Usual on suicidal ideation in chronic depression: Results of a randomized-clinical trial.

Journal of Affective Disorders August 2016 Thomas Forkmann, Eva‐lotta Brakemeier, Tobias Teismann et al.

Suicidal ideation (SI) is common in chronic depression, but only limited evidence exists for the assumption that psychological treatments for depression are effective for reducing SI. In the present study, the effects of Mindfulness-based Cognitive Therapy (MBCT; group version) plus treatment-as-usual (TAU: individual treatment by either a psychiatrist or a licensed psychotherapist, including...

DOI: 10.1016/j.jad.2016.01.047 (opens in new tab) Full text (opens in new tab) Chronic depression Mindfulness-based cognitive therapy Persistent depression Rct +1

Should ketamine be used for the clinical treatment of depression?

Australasian Psychiatry August 1, 2016 Shalini Arunogiri, Nicholas A Keks, Judy Hope

Objective: There has been widespread interest from the public and media in the potential of ketamine as a novel treatment for depression. This paper reviews whether current evidence supports the use of ketamine for the clinical treatment of depression. Conclusions: Clinical trials have investigated the use of intravenous ketamine for the treatment of depressive symptoms over the past 15 years....

KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.

Depression and Anxiety August 2016 William V Bobo, Jennifer L. Vande Voort, Paul E Croarkin et al.

There is an urgent need for more rapidly effective pharmacotherapies for major depressive disorder and bipolar disorder (BP) that are efficacious and tolerable for depressed patients who respond poorly to conventional treatments. Multiple controlled trials have now demonstrated a rapid, nonsustained antidepressive response to a single intravenous infusion of ketamine. Early controlled studies...

Repeated intravenous ketamine benefits patients with treatment‐resistant depression

The Brown University Psychopharmacology Update August 1, 2016

Intravenous ketamine administered twice a week or three times a week resulted in sustained antidepressant effects compared with placebo in a group of patients with treatment‐resistant depression, a new study has found. Based on similar results between the two dosing frequencies, the researchers indicated that a twice‐weekly regimen could serve as an initial repeated‐dose strategy in this...

Using Oral and Intranasal Dosage Forms of Ketamine for Managing Treatment-Resistant Depression: A Review of the Literature

International Journal of Medical Students July 27, 2016 Patrick Arthur Twohig, Vaughn Huckfeldt

A lack of effective treatment for patients with treatment-resistant depression (TRD) has led to the evaluation of ketamine, an N-methyl- D-aspartate receptor antagonist. Despite the demonstrated short-term benefits of using intravenous (IV) ketamine, side effects and the difficulty in administering ketamine outside the health-care setting has raised interest in alternative dosage forms....

Effectiveness of Mindfulness Training in Enhancing Executive Function and Decreasing Symptoms of Depression and Anxiety in Patients with Multiple Sclerosis (MS)

July 22, 2016 M. Amiri, M. Rabiei, V. Donyavi

The purpose of the present study was to evaluate the effectiveness of mindfulness training in enhancing executive function and decreasing symptoms of depression and anxiety in multiple sclerosis patients. The population in this study consisted of people with MS who referred to Karaj city MS society in 1394. These people didn’t experience medicinal changes during the study period and their...

The Relationship between Mindfulness and Cognitive Emotion Regulation and Depression among University Students

International Journal of Academic Research in Psychology July 15, 2016 Majid Sadoughi, Fatemeh Hesampour 2 citations

Admission at university can be considered as a critical phase in life of young students, leading them to enter a greater society and experience a different educational, social, and cultural setting.Generally, these drastic changes in their personal and social lives would be accompanied by intense anxiety and stress, negatively influencing their performance and efficiency; as a result, their...

Turning Towards or Turning Away: A Comparison of Mindfulness Meditation and Guided Imagery Relaxation in Patients with Acute Depression.

Behavioural and Cognitive Psychotherapy July 2016 Ana Costa, Thorsten Barnhofer

Disengaging from maladaptive thinking is an important imperative in the treatment of depression. Mindfulness training is aimed at helping patients acquire relevant skills for this purpose. It remains unclear, however, whether this practice is helpful when patients are acutely depressed. In order to investigate effects of mindfulness on symptoms and self-regulatory capacities in this group, the...

Placebo‐controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression

Acta Psychiatrica Scandinavica July 1, 2016 C. Loo, Verònica Gálvez, E. O'Keefe et al.

This pilot study assessed the feasibility, efficacy and safety of an individual dose‐titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine.

Effects of Mindfulness-Based Cognitive Therapy on Body Awareness in Patients with Chronic Pain and Comorbid Depression

Frontiers in Psychology June 30, 2016 Marasha De Jong, Sara W. Lazar, Kiran Hug et al. 200 citations

Body awareness has been proposed as one of the major mechanisms of mindfulness interventions, and it has been shown that chronic pain and depression are associated with decreased levels of body awareness. We investigated the effect of Mindfulness-Based Cognitive Therapy (MBCT) on body awareness in patients with chronic pain and comorbid active depression compared to treatment as usual (TAU; N =...

DOI: 10.3389/fpsyg.2016.00967 (opens in new tab) Mindfulness-based cognitive therapy Clinical psychology Depression economics Population +7

Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder: a meta-analysis of randomised controlled trials.

PLoS One June 15, 2016 Clara Strauss, Kate Cavanagh, Annie Oliver et al.

ObjectiveMindfulness-based interventions (MBIs) can reduce risk of depressive relapse for people with a history of recurrent depression who are currently well. However, the cognitive, affective and motivational features of depression and anxiety might render MBIs ineffective for people experiencing current symptoms. This paper presents a meta-analysis of randomised controlled trials (RCTs) of...

Putting a Hold on the Downward Spiral of Paranoia in the Social World: A Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy in Individuals with a History of Depression.

PLoS One June 10, 2016 Dina Collip, Nicole Geschwind, Frenk Peeters et al.

ContextParanoia embodies altered representation of the social environment, fuelling altered feelings of social acceptance leading to further mistrust. Mindfulness-based cognitive therapy (MBCT) may relieve paranoia and reduce its impact on social acceptance.ObjectiveTo determine whether MBCT alters momentary feeling of paranoia and social acceptance in daily life.DesignRandomized controlled...

Mindfulness-based yoga intervention for women with depression.

Complementary Therapies in Medicine June 2016 Katie J Schuver, Beth A Lewis

The purpose of this study was to examine the efficacy of a 12-week mindfulness-based yoga intervention on depressive symptoms and rumination among depressed women. Prospective, randomized, controlled 12 week intervention pilot study. Depressive symptoms were assessed at baseline, post-intervention (12 weeks), and one-month follow-up. Women with a history of diagnosed depression and currently...

Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla.

Magma June 2016 Yan Li, Angela Jakary, Erin P Gillung et al.

Our aim was to evaluate differences in metabolite levels between unmedicated patients with major depressive disorder (MDD) and healthy controls, to assess changes in metabolites in patients after they completed an 8-week course of mindfulness-based cognitive therapy (MBCT), and to exam the correlation between metabolites and depression severity. Sixteen patients with MDD and ten age- and...

Biomarkers of Resilience in Stress Reduction for Caregivers of Alzheimer's Patients.

Neuromolecular medicine June 2016 Lap Ho, Patricia A. Bloom, Joan G Vega et al.

Caregiving for a dementia patient is associated with increased risk of psychological and physical health problems. We investigated whether a mindfulness-based stress reduction (MBSR) training course for caregivers that closely models the MBSR curriculum originally established by the Center of Mindfulness at the University of Massachusetts may improve the psychological resilience of...

Ketamine enantiomers in the rapid and sustained antidepressant effects.

Therapeutic Advances in Psychopharmacology June 2016 John Muller, Sahana Pentyala, James Dilger et al.

Recent evidence has suggested that the N-methyl-D-aspartate receptor antagonist ketamine shows significant therapeutic effects in major depression and bipolar disorder. This effect is especially important in treatment-resistant depression and depression with suicidal ideation. In this review we explain the mechanism of action, drug efficacy, and the side effects of ketamine; the antidepressive...